Search results for " insulin"

showing 10 items of 237 documents

INSULIN RESISTANCE, STEATOSIS AND PROGRESSION OF FIBROSIS IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C

2010

Background and aim: Insulin resistance (IR) and steatosis have been associated with fibrosis severity in chronic hepatitis C (CHC), but only few studies investigate their role as predictors of disease evolution. We aimed to assess in patients with CHC if IR and steatosis are linked to progression of fibrosis over time. Material and methods: 86 consecutive G1 HCV infected patients with two paired liver biopsies over a period 67±30 months (range, 13-135), were evaluated at baseline by anthropometric and metabolic measurements, including IR (IR= HOMA-IR >2.7). All biopsies were scored by one pathologist for staging and grading (Scheuer). Steatosis was considered significant if =10. Results: At…

HCV INSULIN RESISTANCESettore MED/12 - GastroenterologiaSettore MED/13 - Endocrinologia
researchProduct

Plasma Insulin Levels and Hypoglycemia Affect Subcutaneous Interstitial Glucose Concentration

2018

[EN] Background: Continuous glucose monitoring (CGM) accuracy during hypoglycemia is suboptimal. This might be partly explained by insulin or hypoglycemia-induced changes in the plasma interstitial subcutaneous (SC) fluid glucose gradient. The aim of the present study was to assess the role of plasma insulin (PI) and hypoglycemia itself in the plasma and interstitial SC fluid glucose concentration in patients with type 1 diabetes mellitus. Methods: Eleven subjects with type 1 diabetes (age 36.59.1 years, HbA(1c) 7.90.4% [62.8 +/- 2.02mmol/mol]; mean +/- standard deviation) were evaluated under hyperinsulinemic euglycemia and hypoglycemia. Each subject underwent two randomized crossover clam…

Hypoglycemia; Interstitial glucose; Subcutaneous glucose sensing; Endocrinology Diabetes and Metabolism; Endocrinology; Medical Laboratory TechnologyAdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismHypoglycemiaAffect (psychology)03 medical and health sciences0302 clinical medicineEndocrinologySubcutaneous glucose sensingInternal medicineDiabetes mellitusMedicineHumansInsulinskin and connective tissue diseases030304 developmental biology0303 health sciencesbusiness.industryContinuous glucose monitoringInsulinnutritional and metabolic diseasesInterstitial glucoseExtracellular FluidMiddle Agedmedicine.diseaseHypoglycemiaINGENIERIA DE SISTEMAS Y AUTOMATICA3. Good healthDiabetes and MetabolismMedical Laboratory TechnologyEndocrinologyDiabetes Mellitus Type 1GlucoseInterstitial glucoseFemalesense organsPlasma insulinbusiness
researchProduct

Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group

2011

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in females, with a high prevalence. The etiology of this heterogeneous condition remains obscure, and its phenotype expression varies. Two widely cited previous ESHRE/ASRMsponsored PCOS consensus workshops focused on diagnosis (published in 2004) and infertility management (published in 2008), respectively. The present third PCOS consensus report summarizes current knowledge and identifies knowledge gaps regarding various women's health aspects of PCOS. Relevant topics addressed-all dealt with in a systematic fashion-include adolescence, hirsutism and acne, contraception, menstrual cycle abnormalities, quality of life, e…

Infertilitymedicine.medical_specialtyConsensusMEDLINEmetabolic syndromeSettore MED/13 - EndocrinologiaPolycystic Ovary Syndrome Adolescence Metabolism Cardiovascular riskMetabolic DiseasesQuality of lifeSDG 3 - Good Health and Well-beingPregnancyRisk Factorscardiovascular diseaseNeoplasmsinsulin resistancemedicineHumanscancerPolycystic ovary syndromehirsutismhirsutismGynecologybiologypregnancy complicationsbusiness.industryPolycystic ovary syndrome (PCOS)cancer; cardiovascular disease; contraception; hirsutism; insulin resistance; metabolic syndrome; Polycystic ovary syndrome; pregnancy complications; quality of life; type 2 diabetesObstetrics and GynecologyAnti-Müllerian hormonemedicine.diseasePolycystic ovarycontraceptionquality of lifeReproductive MedicineCardiovascular DiseasesFamily medicinebiology.proteinEtiologyFemaletype 2 diabetesbusinessInfertility Female
researchProduct

The regulation of efferocytosis signaling pathways and adipose tissue homeostasis in physiological conditions and obesity: Current understanding and …

2022

Obesity is associated with changes in the resolution of acute inflammation that contribute to the clinical complications. The exact mechanisms underlying unresolved inflammation in obesity are not fully understood. Adipocyte death leads to pro-inflammatory adipose tissue macrophages, stimulating additional adipocyte apoptosis. Thus, a complex and tightly regulated process to inhibit inflammation and maintain homeostasis after adipocyte apoptosis is needed to maintain health. In normal condition, a specialized phagocytic process (efferocytosis) performs this function, clearing necrotic and apoptotic cells (ACs) and controlling inflammation. For efficient and continued efferocytosis, phagocyt…

InflammationAdipose TissueEndocrinology Diabetes and MetabolismPublic Health Environmental and Occupational HealthHomeostasisHumansObesityadipose tissue homeostasis clearance of apoptotic adipocytes continual efferocytosis high fat diet insulin resistance metabolic connections metabolic inflammation therapeutic strategiesSignal TransductionObesity Reviews
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?

2019

The interesting article by Yamabe et al.1 showed, using continuous glucose monitoring, that insulin degludec (I‐Deg) was associated with a high percentage of time with nocturnal hypoglycemia than with insulin glargine 300 U/mL (I‐G300; P = 0.02). However, we observe that some possible confounding factors might have influenced the results, such as differences in concomitant medications, use of the same titration protocol for both kinds of insulin or differences in glucose levels. This is also a recurrent problem in clinical trials, which sometime produce conflicting results. In fact, the study of Yamabe et al. is partly in agreement with some recently published clinical trials that gave diff…

Insulin degludecBlood Glucosemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentdiabetes insulin clinical trials hypoglicemiaInsulinsInsulin GlargineHypoglycemiaDiseases of the endocrine glands. Clinical endocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsLetters to the EditorLetter to the EditorGlycated HemoglobinInsulin glarginebusiness.industryInsulinBlood Glucose Self-Monitoringnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseRC648-665HypoglycemiaClinical trialInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 2businessmedicine.drug
researchProduct

Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observat…

2021

While data on the efficacy and safety of continuous glucose monitoring (CGM) exist across a broad age spectrum, it is limited in very young children with type 1 diabetes (T1D). We aimed to assess real-world data in this high-risk population, focusing on glycemic variability and metrics beyond HbA1c. A 12-month multi-national, prospective, observational, registry-based cohort study in children with T1D aged 1-7 years compared glucose control using real-time CGM and using fingerstick blood glucose monitoring (BGM) alone. The prespecified primary endpoint was a difference in coefficient of variation (CV) between the CGM users and BGM-only cohort. Among 227 individuals using insulin pumps (42% …

Insulin pumpBlood GlucosePediatricsmedicine.medical_specialtyendocrine system diseasesFingerstickEndocrinology Diabetes and MetabolismPopulationChildren; Continuous glucose monitoring; Insulin pump; Toddlers; Type 1 diabetesCohort StudiesHDE END PEDEndocrinologyInsulin Infusion SystemsInternal MedicinemedicineHumansHypoglycemic AgentsInsulinInsulin pumpeducationChildChildrenContinuous glucose monitoringchildren; continuous glucose monitoring; insulin pump; toddlers; type 1 diabetesGlycemicBlood glucose monitoringGlycated HemoglobinToddlerseducation.field_of_studyType 1 diabetesmedicine.diagnostic_testEndocrinology; Metabolismbusiness.industryBlood Glucose Self-Monitoringnutritional and metabolic diseasesDiabetes type 1medicine.diseaseType 1 diabetesDiabetes Mellitus Type 1GlucoseChild PreschoolCohortbusinessCohort studyDiabetes Obesity & Metabolism
researchProduct

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

2022

Purpose We aimed to evaluate the near-final height (nFHt) in a large cohort of pediatricpatients with growth hormone deficiency (GHD) and to elaborate a new predictive method of nFHt. Methods We recruited GHD patients diagnosed between 1987 and 2014 and followed-up until nFHt. To predict the values of nFHt, each predictor was run in a univariable spline. Results We enrolled 1051 patients. Pre-treatment height was -2.43 SDS, lower than parental height (THt) (-1.09 SDS, p < 0.001). The dose of recombinant human GH (rhGH) was 0.21mg/kg/week at start of treatment. nFHt was -1.08 SDS (height gain 1.27 SDS), higher than pre-treatment height (p < 0.001) and comparable to THt. 1.6% of the pat…

Insulin-like growth factor 1Human Growth HormoneEndocrinology Diabetes and MetabolismPubertyFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; PredictionDwarfismGrowthBody HeightCohort StudiesEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaGrowth hormone retestingPituitaryFinal heightGrowth HormoneFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; Prediction; Body Height; Child; Cohort Studies; Growth Hormone; Humans; Puberty; Dwarfism Pituitary; Human Growth HormoneHumansGrowth hormone deficiencyLMG methodDwarfism PituitaryPredictionChildFinal height Growth Growth hormone deficiency Growth hormone retesting Insulin-like growth factor 1 LMG method Prediction
researchProduct

Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli.

2006

Abstract Purpose: Recent in vitro studies suggested that the autocrine leptin loop might contribute to breast cancer development by enhancing cell growth and survival. To evaluate whether the leptin system could become a target in breast cancer therapy, we examined the expression of leptin and its receptor (ObR) in primary and metastatic breast cancer and noncancer mammary epithelium. We also studied whether the expression of leptin/ObR in breast cancer can be induced by obesity-related stimuli, such as elevated levels of insulin, insulin-like growth factor-I (IGF-I), estradiol, or hypoxic conditions. Experimental Design: The expression of leptin and ObR was examined by immunohistochemistry…

LeptinCancer ResearchER-BETAmedicine.medical_treatmentHYPOXIA-INDUCIBLE FACTOR-1NeoplasmsTumor Cells CulturedBreastInsulin-Like Growth Factor Iskin and connective tissue diseasesReceptorAged 80 and overEstradiolIGF-I RECEPTORCELL-LINEReverse Transcriptase Polymerase Chain ReactionLeptindigestive oral and skin physiologyCarcinoma Ductal BreastMiddle AgedMetastatic breast cancerINSULINCell HypoxiaESTROGENOncologyDisease ProgressionIGF-I RECEPTOR; HYPOXIA-INDUCIBLE FACTOR-1; OB GENE; GROWTH-FACTOR; CELL-LINE; ER-BETA; ESTROGEN; ALPHA; INSULIN; MCF-7Receptors LeptinFemaleOB GENEhormones hormone substitutes and hormone antagonistsAdultmedicine.medical_specialtyGROWTH-FACTORBreast NeoplasmsReceptors Cell SurfaceBreast cancerInternal medicinemedicineBiomarkers TumorHumansObesityAutocrine signallingAgedLeptin receptorbusiness.industryInsulinmedicine.diseaseALPHAEndocrinologyTumor progressionCase-Control StudiesMCF-7business
researchProduct

Metabolic adaptations in neonatal mother-deprived rabbits

2010

[EN] In order to study the metabolic adaptation in response to 48 h transient doe-litter separation (DLS) in young rabbits (5 rabbits/d group) between postnatal 9 and 11 d, plasma concentrations of thyroid hormones T3 and T4, insulin, leptin, glucose, triglycerides (TG), and free fatty acids (FFA) were examined before (6-8 d), during (9-11 d), and after separation (12-16 d). T3 concentrations in newborn control rabbits gradually increased from 0.6 ng/mL at postnatal 6 d to 1.0 ng/mL at postnatal 16 d, whereas those of T4 remained fairly constant (25 ng/mL) up to postnatal 14 d, when T4 gradually declined to 8 ng/mL. T3 values of DLS newborn rabbits did not differ from those of controls at p…

Leptinmedicine.medical_specialtymaternal separation thyroid hormones insulin leptin glucose rabbitsSettore AGR/19 - Zootecnica SpecialeTriiodothyronineThyroid hormonesInsulinmedicine.medical_treatmentLeptinBlood sugarRabbitBiologyGlucoseEndocrinologyInternal medicineThyroid hormonesBlood plasmaPlasma concentrationmedicineInsulinEndocrine systemAnimal Science and ZoologyMaternal separation
researchProduct